Is it a good or bad thing when a stock surpasses resistance at the 200-day simple moving average?
Is it a good or bad thing when a stock surpasses resistance at the 50-day simple moving average?
Detailed price information for Unitedhealth Group (UNH-N) from The Globe and Mail including charting and trades.
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
Detailed price information for Envista Holdings Corp (NVST-N) from The Globe and Mail including charting and trades.
Legend Biotech's (LEGN) multiple myeloma therapy Carvykti is facing growing competitive pressure as
Detailed price information for Legend Biotech Corp ADR (LEGN-Q) from The Globe and Mail including charting and trades.
Legend Biotech (NASDAQ:LEGN) presents a compelling equity thesis centered on transforming breakthrough oncology innovation into a high-margin, cash-generative cell therapy franchise. Maintaining a fortress balance sheet anchored by approximately $965 million in cash, cash equivalents, and time deposits as of June 30, fortified by $212 million in net proceeds from a public offering of American […]
Ingrid Zhang, an accomplished global biopharmaceutical leader, joins Legend Biotech following a comprehensive Board-led search processBRIDGEWATER, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) ("Legend Biotech" or the "Company"), a global leader in cell therapy, today announced that its Board of Directors has appointed Ingrid Zhang as Chief Executive Officer, effective September 15, 2026. Ingrid Zhang succeeds Alan Bash, who has served as Interim Chief Execut
Legend Biotech (LEGN) drew fresh investor attention after announcing that interim CEO Alan Bash will speak at the Morgan Stanley Global Healthcare Conference on September 15, 2026. The company plans to highlight its CAR-T focus and commercial footprint during the event. Legend Biotech’s share price has been volatile, with a 13.91% 1 month share price return, followed by a 41.27% decline over 3 months and a 38.25% fall in 1 year total shareholder return. This suggests that long term momentum...
BRIDGEWATER N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Alan Bash, interim Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference in New York, NY on Tuesday, September 15, 2026, at 2:35 p.m. ET. The live webcast will be available to investors and other interested parties by accessing the Investor Relations section of the Legend Bi
This is the newest page. Registered accounts read further back.